Terms: = Germ cell tumor AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
1189 results:
1. YANK2 activated by Fyn promotes glioma tumorigenesis via the mtor-independent p70S6K activation pathway.
Shi Y; Cheng Y; Wang W; Tang L; Li W; Zhang L; Yuan Z; Zhu F; Duan Q
Sci Rep; 2024 May; 14(1):10507. PubMed ID: 38714727
[TBL] [Abstract] [Full Text] [Related]
2. Gedunin modulates cellular growth and apoptosis in glioblastoma cell lines.
Stouffer M; Wandling E; Dickson L; Lin S; Duan H; Powe E; Jean-Louis D; Tiwari AK; Amos S
Cancer Rep (Hoboken); 2024 May; 7(5):e2051. PubMed ID: 38702989
[TBL] [Abstract] [Full Text] [Related]
3. PUMC-MB1 is a novel group 3 medulloblastoma preclinical model, sensitive to PI3K/mtor dual inhibitor.
Wang S; Zhang D; Wang J; Peng X; Sun H; Ji Y; Yang Z; Bian X; Hou Y; Ge M; Liu Y
J Neurooncol; 2024 May; 168(1):139-149. PubMed ID: 38662151
[TBL] [Abstract] [Full Text] [Related]
4. Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
Dvorakova K; Skarkova V; Vitovcova B; Soukup J; Vosmikova H; Pleskacova Z; Skarka A; Bartos MC; Krupa P; Kasparova P; Petera J; Rudolf E
BMC Cancer; 2024 Apr; 24(1):509. PubMed ID: 38654280
[TBL] [Abstract] [Full Text] [Related]
5. Multi-omics technologies and molecular biomarkers in brain tumor-related epilepsy.
Du Y; Li R; Fu D; Zhang B; Cui A; Shao Y; Lai Z; Chen R; Chen B; Wang Z; Zhang W; Chu L
CNS Neurosci Ther; 2024 Apr; 30(4):e14717. PubMed ID: 38641945
[TBL] [Abstract] [Full Text] [Related]
6. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
[TBL] [Abstract] [Full Text] [Related]
7. Targeting the EGFR pathway: An alternative strategy for the treatment of tuberous sclerosis complex?
Schachenhofer J; Gruber VE; Fehrer SV; Haider C; Glatter S; Liszewska E; Höftberger R; Aronica E; Rössler K; Jaworski J; Scholl T; Feucht M
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12974. PubMed ID: 38562027
[TBL] [Abstract] [Full Text] [Related]
8. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
[TBL] [Abstract] [Full Text] [Related]
9. Exploring the combined anti-cancer effects of sodium butyrate and celastrol in glioblastoma cell lines: a novel therapeutic approach.
Kartal B; Denizler-Ebiri FN; Güven M; Taşpınar F; Canpınar H; Çetin S; Karaduman T; Küççüktürk S; Castresana J; Taşpınar M
Med Oncol; 2024 Mar; 41(5):97. PubMed ID: 38532150
[TBL] [Abstract] [Full Text] [Related]
10. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract] [Full Text] [Related]
11. Discrete Mechanistic Target of Rapamycin Signaling Pathways, Stem cells, and Therapeutic Targets.
Jhanwar-Uniyal M; Zeller SL; Spirollari E; Das M; Hanft SJ; Gandhi CD
Cells; 2024 Feb; 13(5):. PubMed ID: 38474373
[TBL] [Abstract] [Full Text] [Related]
12. Effect of gold-conjugated resveratrol nanoparticles on glioma cells and its underlying mechanism.
Liu X; Guo Z; Li J; Wu D; Liu Z; Guan C; Guan Y; Lu X
Biomed Mater Eng; 2024; 35(3):279-292. PubMed ID: 38461500
[TBL] [Abstract] [Full Text] [Related]
13. Daurisoline suppress glioma progression by inhibiting autophagy through PI3K/AKT/mtor pathway and increases TMZ sensitivity.
Yin HT; Hui-Lu ; Yang JH; Li Q; Li M; Zhao QQ; Wen ZP
Biochem Pharmacol; 2024 May; 223():116113. PubMed ID: 38460907
[TBL] [Abstract] [Full Text] [Related]
14. CD133 significance in glioblastoma development: in silico and in vitro study.
Abdoli Shadbad M; Nejadi Orang F; Baradaran B
Eur J Med Res; 2024 Mar; 29(1):154. PubMed ID: 38448914
[TBL] [Abstract] [Full Text] [Related]
15. Emerging therapeutic strategies for metastatic uveal melanoma: Targeting driver mutations.
Liu XL; Run-Hua Z; Pan JX; Li ZJ; Yu L; Li YL
Pigment Cell Melanoma Res; 2024 May; 37(3):411-425. PubMed ID: 38411373
[TBL] [Abstract] [Full Text] [Related]
16. Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.
Ezzati S; Salib S; Balasubramaniam M; Aboud O
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396993
[TBL] [Abstract] [Full Text] [Related]
17. Astaxanthin Inhibits H
Yan T; Ding F; Zhang Y; Wang Y; Wang Y; Zhang Y; Zhu F; Zhang G; Zheng X; Jia G; Zhou F; Zhao Y; Zhao Y
Mar Drugs; 2024 Jan; 22(2):. PubMed ID: 38393028
[TBL] [Abstract] [Full Text] [Related]
18. Antiproliferative effect of Potentilla fulgens on glioblastoma cancer cells through downregulation of Akt/mtor signaling pathway.
Kandemir SI; Ipek P
J Cancer Res Ther; 2023 Oct; 19(7):1818-1824. PubMed ID: 38376284
[TBL] [Abstract] [Full Text] [Related]
19. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma.
Nghiemphu PL; Vitte J; Dombi E; Nguyen T; Wagle N; Ishiyama A; Sepahdari AR; Cachia D; Widemann BC; Brackmann DE; Doherty JK; Kalamarides M; Giovannini M
J Neurooncol; 2024 Apr; 167(2):339-348. PubMed ID: 38372904
[TBL] [Abstract] [Full Text] [Related]
20. Repeat surgery of recurrent glioma for molecularly informed treatment in the age of precision oncology: A risk-benefit analysis.
Alhalabi OT; Dao Trong P; Kaes M; Jakobs M; Kessler T; Oehler H; König L; Eichkorn T; Sahm F; Debus J; von Deimling A; Wick W; Wick A; Krieg SM; Unterberg AW; Jungk C
J Neurooncol; 2024 Apr; 167(2):245-255. PubMed ID: 38334907
[TBL] [Abstract] [Full Text] [Related]
[Next]
